Solasia Pharma K.K. revised consolidated earnings guidance for the year ending December 31, 2020. For the year, the company expects revenue of JPY 450 million compared to the previous range of JPY 500 million to JPY 2,000 million, operating loss of JPY 4,200 million compared to the previous range of JPY 2,900 million to JPY 2,000 million, loss of JPY 4,200 million compared to the previous range of JPY 2,900 million to JPY 2,000 million and basic loss per share of JPY 35.78 compared to the previous range of JPY 24.48 to JPY 16.89.